These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

308 related articles for article (PubMed ID: 31169881)

  • 1. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
    Gillezeau CN; van Gerwen M; Ramos J; Liu B; Flores R; Taioli E
    Carcinogenesis; 2019 Nov; 40(11):1320-1331. PubMed ID: 31169881
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HMGB1 and Its Hyperacetylated Isoform are Sensitive and Specific Serum Biomarkers to Detect Asbestos Exposure and to Identify Mesothelioma Patients.
    Napolitano A; Antoine DJ; Pellegrini L; Baumann F; Pagano I; Pastorino S; Goparaju CM; Prokrym K; Canino C; Pass HI; Carbone M; Yang H
    Clin Cancer Res; 2016 Jun; 22(12):3087-96. PubMed ID: 26733616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Changes of mesothelin and osteopontin levels over time in formerly asbestos-exposed power industry workers.
    Felten MK; Khatab K; Knoll L; Schettgen T; Müller-Berndorff H; Kraus T
    Int Arch Occup Environ Health; 2014 Feb; 87(2):195-204. PubMed ID: 23423281
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glycodelin is a potential novel follow-up biomarker for malignant pleural mesothelioma.
    Schneider MA; Muley T; Kahn NC; Warth A; Thomas M; Herth FJ; Dienemann H; Meister M
    Oncotarget; 2016 Nov; 7(44):71285-71297. PubMed ID: 27713145
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T; Dienemann H; Herth FJ; Thomas M; Meister M; Schneider J
    J Thorac Oncol; 2013 Jul; 8(7):947-51. PubMed ID: 23777840
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of New Biomarkers in the Prediction of Malignant Mesothelioma in Subjects with Environmental Asbestos Exposure.
    Demir M; Kaya H; Taylan M; Ekinci A; Yılmaz S; Teke F; Sezgi C; Tanrikulu AC; Meteroglu F; Senyigit A
    Lung; 2016 Jun; 194(3):409-17. PubMed ID: 27032653
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
    Bonotti A; Simonini S; Pantani E; Giusti L; Donadio E; Mazzoni MR; Chella A; Marconi L; Ambrosino N; Lucchi M; Mussi A; Cristaudo A; Foddis R
    Int J Biol Markers; 2017 Mar; 32(1):e126-e131. PubMed ID: 27646775
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mesothelin is more useful in pleural effusion than in serum in the diagnosis of pleural mesothelioma.
    Ferro P; Canessa PA; Battolla E; Dessanti P; Franceschini MC; Chiaffi L; Morabito A; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2013 Jun; 33(6):2707-13. PubMed ID: 23749930
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum biomarkers in patients with mesothelioma and pleural plaques and healthy subjects exposed to naturally occurring asbestos.
    Bayram M; Dongel I; Akbaş A; Benli I; Akkoyunlu ME; Bakan ND
    Lung; 2014 Feb; 192(1):197-203. PubMed ID: 24170217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
    Cristaudo A; Bonotti A; Simonini S; Vivaldi A; Guglielmi G; Ambrosino N; Chella A; Lucchi M; Mussi A; Foddis R
    J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnostic and Prognostic Biomarkers in the Rational Assessment of Mesothelioma (DIAPHRAGM) study: protocol of a prospective, multicentre, observational study.
    Tsim S; Kelly C; Alexander L; McCormick C; Thomson F; Woodward R; Foster JE; Stobo DB; Paul J; Maskell NA; Chalmers A; Blyth KG
    BMJ Open; 2016 Nov; 6(11):e013324. PubMed ID: 27884852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mesothelin in serum and pleural effusion in the diagnosis of malignant pleural mesothelioma with non-positive cytology.
    Franceschini MC; Ferro P; Canessa PA; Battolla E; Dessanti P; Valentino A; Casolari L; Fontana V; Pezzi R; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2014 Dec; 34(12):7425-9. PubMed ID: 25503183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma.
    Creaney J; Dick IM; Meniawy TM; Leong SL; Leon JS; Demelker Y; Segal A; Musk AW; Lee YC; Skates SJ; Nowak AK; Robinson BW
    Thorax; 2014 Oct; 69(10):895-902. PubMed ID: 25037982
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of the Diagnostic Performance of Fibulin-3 and Mesothelin in Patients with Pleural Effusions from Malignant Mesothelioma.
    Battolla E; Canessa PA; Ferro P; Franceschini MC; Fontana V; Dessanti P; Pinelli V; Morabito A; Fedeli F; Pistillo MP; Roncella S
    Anticancer Res; 2017 Mar; 37(3):1387-1391. PubMed ID: 28314308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Utility of osteopontin and serum mesothelin in malignant pleural mesothelioma diagnosis and prognosis assessment.
    Grigoriu BD; Scherpereel A; Devos P; Chahine B; Letourneux M; Lebailly P; Grégoire M; Porte H; Copin MC; Lassalle P
    Clin Cancer Res; 2007 May; 13(10):2928-35. PubMed ID: 17504993
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnostic value of fibulin-3 for malignant pleural mesothelioma: A systematic review and meta-analysis.
    Ren R; Yin P; Zhang Y; Zhou J; Zhou Y; Xu R; Lin H; Huang C
    Oncotarget; 2016 Dec; 7(51):84851-84859. PubMed ID: 27769044
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mesothelin, Calretinin, and Megakaryocyte Potentiating Factor as Biomarkers of Malignant Pleural Mesothelioma.
    Jiménez-Ramírez C; Casjens S; Juárez-Pérez CA; Raiko I; Del Razo LM; Taeger D; Calderón-Aranda ES; Rihs HP; Acosta-Saavedra LC; Weber DG; Cabello-López A; Pesch B; Ochoa-Vázquez MD; Burek K; Torre-Bouscoulet L; Pérez-Padilla JR; García-Bazan EM; Brüning T; Johnen G; Aguilar-Madrid G
    Lung; 2019 Oct; 197(5):641-649. PubMed ID: 31267149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical significance of pleural effusion mesothelin in malignant pleural mesothelioma.
    Yamada S; Tabata C; Tabata R; Fukuoka K; Nakano T
    Clin Chem Lab Med; 2011 Oct; 49(10):1721-6. PubMed ID: 21692685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J; Yeoman D; Demelker Y; Segal A; Musk AW; Skates SJ; Robinson BW
    J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serum soluble mesothelin-related protein (SMRP) and fibulin-3 levels correlate with baseline malignant pleural mesothelioma (MPM) tumor volumes but are not useful as biomarkers of response in an immunotherapy trial.
    Katz SI; Roshkovan L; Berger I; Friedberg JS; Alley EW; Simone CB; Haas AR; Cengel KA; Sterman DH; Albelda SM
    Lung Cancer; 2021 Apr; 154():5-12. PubMed ID: 33561782
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.